The forthcoming committee meeting to discuss metreleptin for treating lipodystrophy on Wednesday 24 October 2018 has been rearranged to enable the company to prepare and submit additional information for committees consideration.
Metreleptin for treating lipodystrophy will be now considered by committee on Tuesday 12 February 2019.